This product is for research use only and is not for human consumption or therapeutic use.
CAS Number:
1442472-39-0
Purity:
99.33
Molecular Formula:
C24H21BrFN5O2
Molecular Weight:
510.36
Alternative Names:
DCC-2618
- Data sheet: View or download
- MSDS: View or download
- Protocol: View or download
Product Description:
Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2)[1][2]. DCC-2618 exerts antineoplastic effect and induces apoptosis[3].
Storage Temperature:
-20°C, 3 years; 4°C, 2 years (Powder)